Otonomy (OTIC) Osake Kurssi

The business model of Otonomy Inc focuses on developing and commercializing innovative treatments for diseases and disorders of the ear. The company utilizes its proprietary technology platform to design and deliver drug therapies directly into the ear, targeting specific areas to address conditions such as hearing loss, tinnitus, and ear infections. By focusing on the otology market, Otonomy aims to provide patients with improved treatment options that are more effective and convenient. With a strong emphasis on research and development, Otonomy Inc strives to bring breakthrough therapies to market and make a positive impact on the lives of individuals with ear-related conditions.

Otonomy Inc is primarily active in the biotechnology and pharmaceutical industries.

Otonomy Inc is a biopharmaceutical company specializing in developing and commercializing innovative therapeutics for diseases affecting the ear. Founded in 2008, the company has focused on treating conditions such as Ménière's disease, chronic otitis media, and hearing loss. Otonomy utilizes its proprietary technology, called OTO-313, to deliver targeted drug treatments to the ear, aiming to restore normal function and improve patient outcomes. Through its dedicated research and development efforts, Otonomy aims to address the unmet medical needs of individuals suffering from various ear-related disorders. This commitment has positioned Otonomy as a leader in the field of otology.

Some significant milestones achieved by Otonomy Inc include the FDA approval of their product Otiprio, a treatment for pediatric patients with middle ear effusion, the successful completion of Phase 3 clinical trials for their product OTIVIDEX, a potential treatment for Meniere's disease, and the initiation of Phase 1/2 clinical trials for their product OTO-313, targeting tinnitus. Otonomy Inc has also entered into strategic partnerships and collaborations with companies like AGTC and CFFT to further advance their pipeline and enhance their expertise in gene therapy and cystic fibrosis. These accomplishments demonstrate Otonomy Inc's commitment to developing innovative solutions for hearing and balance disorders.

Otonomy Inc is primarily present in the United States.

Otonomy Inc represents a strong corporate philosophy centered around advancing hearing healthcare. They are committed to improving the lives of patients with ear and hearing disorders by developing innovative treatments. Otonomy Inc values patient-centricity, scientific excellence, and collaboration with healthcare professionals. They strive to deliver safe and effective therapies for various ear conditions, such as Meniere's disease and pediatric ear infections. With their dedication to research and development, Otonomy Inc aims to address unmet medical needs and enhance the quality of life for individuals suffering from ear-related ailments.

7 analyytikkoa arvioi tällä hetkellä Otonomy-osaketta: 6 suosittaa ostoa, 1 pitoa ja 0 myyntiä.

Otonomy Analyytikkojen kursstavoitteet 2026

Otonomy-osake (OTIC) on listattuna 5 pörssissä, muun muassa: NASDAQ (OTIC), SIX (Zürich) (7OT.SW), Frankfurt (7OT.F), München (7OT.MU), Düsseldorf (7OT.DU).

Otonomy Inc. is a biopharmaceutical company that focuses on the development and commercialization of products for the treatment of ear diseases. The company was founded in 2008 and is headquartered in San Diego, California. The company is divided into two business segments: Ear and Neurology. In the Ear segment, the company focuses on developing innovative products for the treatment of ear diseases such as hearing loss, tinnitus, and ear infections. In the Neurology segment, the company is dedicated to treating central nervous system disorders such as multiple sclerosis and migraine. One of Otonomy Inc's main products is OTIPRIO, an antibiotic for the treatment of acute middle ear infection in children. It is injected directly into the affected ear and reduces the need for systemic antibiotic therapy. OTIPRIO is the first and only product approved by the FDA for treating ear infections in a doctor's office. Another important product of Otonomy Inc is OTIVIDEX, a medication for treating patients with Meniere's disease, an inner ear disorder that causes dizziness, hearing loss, and ringing in the ears. OTIVIDEX has been studied in a clinical trial and has shown significant benefits compared to placebo. The company also has other products in development, including OTO-313, a medication for treating tinnitus, and OTO-413, a medication for treating hearing loss. Both products are in clinical trials. Otonomy Inc has a strong pipeline of products in development and is continuously working to expand its product range. This strategy is aimed at ensuring the long-term growth of the company and expanding treatment options for patients with ear and neurological diseases. The company's financing is primarily through the sale of stocks and investments from venture capital funds. The company went public in 2014. Overall, Otonomy Inc's business model is focused on developing and successfully commercializing innovative products for the treatment of ear and neurological diseases. The company relies on a strong pipeline of products in development to ensure long-term growth.

Liikevaihtoa ei voida laskea Otonomy:lle tällä hetkellä.

Voittoa ei voida laskea Otonomy:lle tällä hetkellä.

P/E-suhdetta ei voida laskea Otonomy:lle tällä hetkellä.

P/S-suhdetta ei voida laskea Otonomy:lle tällä hetkellä.

Otonomy:n Eulpool-laatuscore on 2/10.

Otonomy:n ISIN on US68906L1052. ISIN (International Securities Identification Number) on maailmanlaajuisesti ainutlaatuinen arvopaperin tunnus.

Otonomy:n WKN on A119VZ. WKN (Wertpapierkennnummer) on kuusinumeroinen saksalainen arvopaperin tunnus.

Otonomy:n ticker on OTIC. Tämä pörssinoteeraus käytetään Otonomy-osakkeiden kauppaan pörssissä.